Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
⏸️ Investing
Is Mayne Pharma Group Ltd's US$652 million acquisition a reason to buy shares?
⏸️ Investing
Leading broker rates these 4 small-cap shares a BUY
⏸️ Investing
4 shares at 52-week highs that could soar higher
⏸️ Investing
The 3 best biotech shares for 2016
⏸️ Investing
4 fast-growing stocks that should be on your watch list
⏸️ Investing
Why the Mayne Pharma Group Ltd share price jumped 4.6%
⏸️ Investing
Your guide to picking winning healthcare stocks
⏸️ Investing
3 stocks on my watch list right now
⏸️ Investing
3 stocks in the buy zone and 1 to avoid
⏸️ Investing
Mayne Pharma Group Ltd reports interim results: Is it time to buy?
⏸️ Investing
Should you add these 3 growth stocks to your portfolio?
⏸️ Investing
5 Stocks slammed on the ASX today
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
